Pfizer Inc. (LON:0Q1N)
London flag London · Delayed Price · Currency is GBP · Price in USD
26.38
+0.21 (0.81%)
At close: Jan 30, 2026

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Primary Care Revenue
27.79B30.14B
Specialty Care Revenue
17.21B16.65B
Oncology Revenue
16.46B15.61B
Global Pharmaceuticals Business (Biopharma) Revenue
61.47B62.40B
Business Innovation (Pfizer CentreOne) Revenue
1.26B1.15B
Revenue (Other)
61.00M81.00M
Revenue (Total)
62.79B63.63B

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
37.18B38.69B
Developed Markets Revenue
16.55B16.06B
Emerging Markets Revenue (Post-FY2023 Reporting)
9.06B8.88B
Revenue (Total)
62.79B63.63B

Revenue by Geography 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
37.18B38.69B
Revenue (Total)
62.79B63.63B

Revenue by Geography 3

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
37.18B38.69B
International Revenue
25.61B24.94B
Revenue (Total)
62.79B63.63B

EBT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Global Pharmaceuticals Business (Biopharma) Earnings
28.80B28.14B
Other Business Activities Earnings
-8.17B-7.38B

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Comirnaty Direct Sales and Alliance Revenue
5.48B5.35B
Eliquis Alliance Revenue and Direct Sales
7.77B7.37B
Paxlovid Revenue
2.87B5.72B
Prevnar Family Revenue
6.34B6.41B
Nurtec ODT/Vydura Revenue
1.41B1.26B
Abrysvo Revenue
751.00M755.00M
Vyndaqel Family Revenue
6.24B5.45B
Xeljanz Revenue
1.11B1.17B
Ibrance Revenue
4.18B4.37B
Updated Sep 28, 2025. Data Source: Fiscal.ai.